Microsatellite instability in prostate cancer by PCR or next-generation sequencing.

ABSTRACT:

Background

Microsatellite instability (MSI) is now being used as a sole biomarker to guide immunotherapy treatment for men with advanced prostate cancer. Yet current molecular diagnostic tests for MSI have not been evaluated for use in prostate cancer.

Methods

We evaluated two next-generation sequencing (NGS) MSI-detection methods, MSIplus (18 markers) and MSI by Large Panel NGS (> 60 markers), and compared the performance of each NGS method to the most widely used 5-marker MSI-PCR detection system. All methods were evaluated by comparison to targeted whole gene sequencing of DNA mismatch-repair genes, and immunohistochemistry for mismatch repair genes, where available.

Results

In a set of 91 prostate tumors with known mismatch repair status (29-deficient and 62-intac

SUBMITTER: Hempelmann JA 

PROVIDER: S-EPMC5904988 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature